Tumor-specific targeting using oncolytic herpes simplex virus type 1 for prostate cancer treatment
Prostate cancer is the most common non-skin cancer, and the second leading cause of cancer-death in men. Current treatments, including androgen withdrawal therapy, are not curative for advanced metastatic disease and new treatment strategies are urgently required. In this regard, oncolytic virothera...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
University of British Columbia
2009
|
| Online Access: | http://hdl.handle.net/2429/13552 |